4月 30, 2024

NOF CORPORATION and Phosphorex Collaborate to Supply Lipid Nanoparticle Formulations Using NOF’s Proprietary Ionizable Lipid, COATSOME® SS Series

Tokyo, Japan, Hopkinton, MA – April 30, 2024 – NOF CORPORATION announced today a collaboration with Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization (“CDMO”), to supply lipid Nanoparticle (LNP) formulations using NOF’s proprietary ionizable lipids, COATSOME® SS Series, further enhancing its leading position in providing LNP based drug delivery solutions to the market.
NOF CORPORATION’s COATSOME® SS Series offers encapsulation of nucleic acids such as mRNA, siRNA, and pDNA. These proprietary ionizable lipids offer efficient drug delivery into the cytoplasm of cells with higher biodegradability and low toxicity, with controlled targeting to organs such as the liver, spleen, and lymph nodes.
Phosphorex has extensive experience as a CDMO for LNPs, and the combination of NOF’s lipid technology and Phosphorex’s LNP manufacturing technology will enable us to provide comprehensive services related to LNP material development, formulation development, and scale-up manufacturing.

PDF: Collaboration Announcement

For more information: Click here